BioSpace News Archive

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announces details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), today highlights three posters presented during the American Association of Cancer Research (AACR) held in New Orleans from April 8-13, 2022.

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), today announced that the first patient has been dosed in the Company’s Phase 1 clinical trial of IO-202, a first-in-class myeloid checkpoint inhibitor targeting Leukocyte Immunoglobulin-Like Receptor B4 (LILRB4, also known as ILT3) for the treatment of patients with advanced solid tumors (NCT05309187).

Health Canada has granted marketing authorization for JARDIANCE® (empagliflozin) 10 mg for the treatment of chronic heart failure in adults as an adjunct to standard of care therapy, Boehringer Ingelheim (Canada) Ltd. and Eli Lilly Canada Inc. have announced.

Catalyst OrthoScience, a medical device company focused on the upper extremity orthopedics market, is pleased to announce that David Sharp has joined Catalyst as Vice President of Global Marketing effective immediately.

The advancement in the field of clinical research has led to identification of several oncogenes which are generally mutated in cancers.

Shoreline Biosciences, Inc. (Shoreline), today announced the presentation of data at the American Association for Cancer Research (AACR) annual meeting in New Orleans, LA, taking place from April 8-13, 2022.

Increasing prevalence of infectious diseases and genetic disorders across the globe, rapid advancements in genomic sequencing techniques, and rising number of genomic research based activities are some key factors expected to drive global market growth.

Increasing prevalence of chronic diseases, rising number of surgical procedures, and growing preference for minimally invasive surgeries are some key factors expected to drive global market growth.

Immunicom, Inc., a clinical-stage biotechnology company pioneering a first-of-its-kind technology platform for immuno-oncology, announced that Dr. Peter Farrell and Michael E. Lehman have joined the Company’s Board of Directors.